Literature DB >> 26124338

Stimulation by Monocyte Chemoattractant Protein-1 Modulates the Ex-vivo Colony Formation by Head and Neck Squamous Cell Carcinoma Cells.

Gunnar Wichmann1, Carolin Körner2, Andreas Boehm2, Christian Mozet2, Andreas Dietz2.   

Abstract

BACKGROUND: The outcome of patients with head and neck squamous cell carcinoma (HNSCC) is still poor. To improve therapy of HNSCC, biomarkers indicating progression of the disease or modifiers with potential as therapeutic targets and therapy need to be investigated. Since monocyte chemoattractant protein (MCP1) is potentially involved in tumorigenesis of HNSCC, we aimed to clarify its role in HNSCC and investigated the influence of stimulation by MCP1 and its depletion using antibodies against MCP1 (anti-MCP1) on colony formation by HNSCC cells.
MATERIALS AND METHODS: Biopsies of HNSCC were treated according to the protocol of the FLAVINO assay with cisplatin, docetaxel, temsirolimus or cilengitide alone, or combined with MCP1 or anti-MCP1. After a 72-h incubation, ethanol-fixed and fluoresceine-isothiocyanate (FITC)-labeled epithelial colonies were counted.
RESULTS: Colony formation was significantly suppressed by MCP1 and 3.3 μM cisplatin, while docetaxel, cilengitide and temsirolimus at concentrations of 0.275, 10 and 0.50 μM caused insignificant effects. Addition of MCP1 to cisplatin, docetaxel and cilengitide increased efficacy of cytostatics in inhibition of colony formation, whereas those with temsirolimus were increased by anti-MCP1 that when applied alone failed to modulate colony formation. Overall regarding facilitated chemosensitivity, there was a statistical trend in favor of MCP1 stimulation over depletion.
CONCLUSION: Our ex vivo results show context-dependent effects of MCP1 in HNSCC cells. An increase of MCP1 level or its addition to cisplatin, docetaxel and cilengitide reduce colony formation but the efficacy of temsirolimus is augmented by MCP1 depletion. These context-dependently opposite outcomes call for further translational investigations in HNSCC. Copyright
© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  FLAVINO assay; HNSCC; MCP1; anti-MCP1; ex-vivo chemoresponse

Mesh:

Substances:

Year:  2015        PMID: 26124338

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  [Preclinical models to establish innovative therapy strategies : Ex‑vivo assessment of head and neck tumor chemo- and immune responses].

Authors:  G Wichmann; A Dietz
Journal:  HNO       Date:  2016-07       Impact factor: 1.284

Review 2.  RGD-Binding Integrins in Head and Neck Cancers.

Authors:  Hanadi Talal Ahmedah; Laurence H Patterson; Steven D Shnyder; Helen M Sheldrake
Journal:  Cancers (Basel)       Date:  2017-05-26       Impact factor: 6.639

3.  Reduced Cytokine Release in Ex Vivo Response to Cilengitide and Cetuximab Is a Marker for Improved Survival of Head and Neck Cancer Patients.

Authors:  Susan Cedra; Susanne Wiegand; Marlen Kolb; Andreas Dietz; Gunnar Wichmann
Journal:  Cancers (Basel)       Date:  2017-09-05       Impact factor: 6.639

Review 4.  Ex Vivo Culture Models to Indicate Therapy Response in Head and Neck Squamous Cell Carcinoma.

Authors:  Imke Demers; Johan Donkers; Bernd Kremer; Ernst Jan Speel
Journal:  Cells       Date:  2020-11-23       Impact factor: 6.600

Review 5.  Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review.

Authors:  Amy J C Dohmen; Justin E Swartz; Michiel W M Van Den Brekel; Stefan M Willems; René Spijker; Jacques Neefjes; Charlotte L Zuur
Journal:  Cancers (Basel)       Date:  2015-08-28       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.